Jeffrey Hackman Purchases 15,000 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Jeffrey Hackman acquired 15,000 shares of the business’s stock in a transaction dated Monday, May 19th. The stock was bought at an average cost of C$9.77 per share, with a total value of C$146,580.00.

Fennec Pharmaceuticals Price Performance

Shares of FRX opened at C$11.50 on Thursday. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company’s fifty day simple moving average is C$8.34 and its 200 day simple moving average is C$8.48. Fennec Pharmaceuticals Inc. has a 1-year low of C$5.65 and a 1-year high of C$11.50. The company has a market cap of C$221.77 million, a price-to-earnings ratio of -194.81 and a beta of 0.25.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.